PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To compare the relative bioavailability and pharmacokinetic characteristics of a newly
developed bepotastine formulation, bepotastine salicylate, with a conventional formulation,
bepotastine besilate, in healthy subjects with a single dose, randomized, open-label,
2-sequence -2period crossover study.